Eli Lilly is deploying its cash pile into untested drug development strategies, including an “App Store” for scientists, as the pharma group aims to shield itself from the expiry of patents on its blockbuster weight-loss drugs.
为了应对减重“爆款”药物专利即将到期的风险，制药企业礼来(Eli Lilly)正将其现金储备投向未经验证的药物开发策略，其中包括面向科学家的“App Store”。
您已阅读4%（309字），剩余96%（7909字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。